Abionyx Pharma
ABNX
Company Profile
Business description
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
Contact
33-43 Avenue Georges Pompidou-Bat D2
Balma31130
FRAT: +33 562249706
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
49
Stocks News & Analysis
stocks
AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event
We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.
stocks
The most popular ASX trades in FY26
A closer look at the stocks and ETFs that captured Aussie investors’ attention in FY26.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,018.10 | 41.40 | -0.46% |
| CAC 40 | 8,299.09 | 138.80 | -1.64% |
| DAX 40 | 24,763.12 | 392.29 | -1.56% |
| Dow JONES (US) | 51,711.65 | 506.93 | -0.97% |
| FTSE 100 | 10,639.17 | 77.80 | -0.73% |
| HKSE | 25,210.81 | 318.15 | 1.28% |
| NASDAQ | 25,137.69 | 553.21 | -2.15% |
| Nikkei 225 | 66,422.60 | 307.00 | 0.46% |
| NZX 50 Index | 13,731.30 | 64.01 | -0.46% |
| S&P 500 | 7,408.30 | 90.66 | -1.21% |
| S&P/ASX 200 | 8,839.00 | 38.60 | -0.43% |
| SSE Composite Index | 3,876.78 | 9.74 | 0.25% |